Gedeon Richter Plc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Gedeon Richter Plc.
Oteseconazole prevented recurrent VVC in two Phase III studies but Phase III data in acute treatment of VVC episodes in women with RVVC, also due this month, are needed to file for US FDA approval in the first half of 2021.
Hungarian firm Gedeon Richter is to expand further its sizeable women’s health portfolio after agreeing to acquire Janssen’s Evra (ethinyl estradiol/norelgestromin) transdermal patch outside of the US for more than a quarter of a billion dollars.
Hungary’s Gedeon Richter enjoyed “rapid sales growth” for its Terrosa teriparatide biosimilar in the first nine months of this year, justifying the firm’s continued advance into biosimilar development.
NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- PregLem Holding SA
- Richter Gedeon Vegyeszeti Gyar Nyrt
- Richter-Helm BioTec GmbH
- FINOX Biotech
- Finox AG